Dirk Keiner | Health Professions | Innovation Excellence Award

Dr. Dirk Keiner | Health Professions | Innovation Excellence Award

Pharmacist at Sophien and Hufeland Clinic Weimar, Germany

Dirk Richard Keiner is an accomplished clinical pharmacist with significant contributions to the advancement of medication safety and clinical pharmacy practice. He is the Head of the Pharmacy at the Sophien- und Hufeland-Klinikum Weimar and holds leadership roles in several professional organizations, including the ADKA Thüringen and G³ – Arbeitsgemeinschaft für moderne Medizin e.V. Keiner has also been deeply involved in education, serving as a lecturer at various institutions such as the SRH University of Health and University of Jena. His innovative research focuses on improving drug therapy management, particularly in geriatrics, oncology, and medication safety. With a vast publication record, numerous awards, and a long-standing commitment to advancing clinical pharmacy, Keiner is a recognized leader in his field.

Professional Profile

Education:

Keiner completed his pharmaceutical studies at the Ernst-Moritz-Arndt University of Greifswald, where he graduated with a degree in Pharmacy in 1996. He conducted his diploma thesis on the analysis of valerian root essential oil. Keiner further pursued a doctorate at the Humboldt University Berlin, earning a Dr. rer. nat. with magna cum laude in 2006. His doctoral research compared various instruments used to measure the quality of life in osteoporosis patients. His strong educational foundation is complemented by various advanced professional qualifications, including specialization in Clinical Pharmacy.

Professional Experience:

Keiner’s career spans multiple leadership roles in both pharmacy practice and academia. He currently serves as the Head of the Pharmacy at the Sophien- und Hufeland-Klinikum Weimar, a position he has held since 2017. Prior to this, he led the pharmacy at SRH Zentralklinikum Suhl and Waldkrankenhaus Eisenberg. His experience also includes extensive work in hospital and community pharmacies. Keiner has been actively involved in professional organizations, including serving as a board member of the ADKA Thüringen and as a delegate in the LAK Thüringen. His diverse professional background showcases his commitment to improving clinical pharmacy and patient care.

Research Interests:

Keiner’s research interests lie primarily in the area of medication safety, particularly in improving drug therapy management for older adults and cancer patients. He focuses on addressing gender-specific aspects of medication therapy and exploring the impact of drug-sun interactions. His work also extends to the development of tools for preventing medication errors and optimizing patient outcomes in clinical settings. Keiner’s research aims to bridge gaps in clinical pharmacy by tackling real-world challenges, such as the safe use of medications in vulnerable populations and the integration of new technologies into clinical practice.

Research Skills:

Keiner’s research skills are rooted in his extensive clinical pharmacy expertise, particularly in medication therapy management and safety. He is adept at conducting in-depth analyses of pharmaceutical interventions, particularly in geriatrics and oncology. Keiner employs various research methodologies, including qualitative and quantitative approaches, to assess the efficacy of drug therapy and the risks associated with certain medications. His ability to translate research findings into practical clinical applications is a hallmark of his work. Moreover, Keiner is skilled in evaluating and improving patient outcomes through the design and implementation of clinical studies that focus on medication errors and therapeutic optimization.

Awards and Honors:

Keiner’s exceptional contributions to clinical pharmacy have earned him numerous prestigious awards. Notable recognitions include the Sanofi-Synthelabo Prize for innovative work in clinical pharmacy, the Authors’ Prize from Krankenhauspharmazie, and the 1st place in the “Patient-Oriented Services” competition by the Dr. Hellmuth-Häussermann Foundation. In 2024, he received the ADKA Innovation Prize for his work on medication safety in the clinical setting. These accolades highlight his dedication to improving patient safety and advancing the field of clinical pharmacy. Keiner’s awards reflect his significant impact on both the scientific community and the practical application of pharmacy in healthcare settings.

Conclusion:

Dirk Richard Keiner’s career exemplifies innovation in clinical pharmacy, with a focus on improving medication safety and therapy management. His strong track record of leadership, research, and education, coupled with several prestigious awards, positions him as a deserving candidate for the Research for Innovation Excellence Award. While there are opportunities for expanding the global and interdisciplinary reach of his work, his contributions to the field of clinical pharmacy are significant, and his leadership in research and education make him a standout nominee.

Publication Top Notes

  1. AMTS Risk Profile Abiraterone | AMTS-Risk profile Abiraterone
    • Authors: Keiner, D.
    • Journal : M
    • Year: 2024
    • Volume: 47(3), pp. 106–114
  2. I’m Sorry, What? | Wie Bitte?
    • Authors: Keiner, D., Hoffmann, K.
    • Journal: Deutsche Apotheker Zeitung
    • Year: 2024
    • Volume: 2024(9)
  3. Probiotics & Co. – What Is Guaranteed? | Probiotics & Co. – What Is Guaranteed?
    • Authors : Keiner, D.
    • Journal: Medizinische Monatsschrift für Pharmazeuten
    • Year: 2023
    • Volume: 46(12)
  4. AMTS Risk Profile Apixaban | AMTS Risk Profile Apixaban
    • Authors : Kei
    • Journal : M
    • Year: 2023
    • Volume: 46(9), pp. 319–326
  5. Check-Change-Control: Management Aspects of Arterial Hypertension in Geriatric Patients | Management Aspects of Arterial Hypertension in Geriatric Patients
    • Authors: Keiner, D., Gockel, H.
    • Journal: Medizinische Monatsschrift für Pharmazeuten
    • Year: 2023
    • Volume: 46(4), pp. 114–123
  6. Risk Pyramid Allopurinol | AMTS-Risk profile Allopurinol
    • Authors: Keiner, D.
    • Journal: Medizinische Monatsschrift für Pharmazeuten
    • Year: 2023
    • Volume: 46(1), pp. 12–19
  7. Much Helps Much – Or Is It? | Much Helps Much – Or Is It Not?
    • Authors: Keiner, D., Picksak, G.
    • Journal : Kr
    • Year: 2022
    • Volume: 43(9), pp. 375–376
  8. Gender-Specific Aspects of Cancer Management – ​​Ready for the Future? | Gender-Specific Aspects in Oncology Care – Ready for the Future?
    • Authors : Ke
    • Journal: Krankenhauspharmazie
    • Year: 2022
    • Volume: 43(9), pp. 353–362
  9. Gender-Specific Aspects of Drug Therapy – The New Clinical Challenge? | Gender-Specific Aspects of Drug Therapy: The New Clinical Challenge?
    • Authors: Keiner, D.
    • Journal: Krankenhauspharmazie
    • Year: 2022
    • Volume: 43(9), pp. 363–366
  10. Gender-Sensitive Medication Management | Gender-Sensitive Medication Management
    • Authors : None,
    • Journal : M
    • Year: 2022
    • Volume: 45(8), pp. 312–314

 

 

Imelda Rocío Guzmán Cervantes | Health Professions | Health Innovator’s Leadership Award

Mrs. Imelda Rocío Guzmán Cervantes | Health Professions | Health Innovator’s Leadership Award

Directora Ejecutiva de Control Analítico at Comisión Federal para la Protección contra Riesgos Sanitarios, Mexico

Mrs. Imelda Rocío Guzmán Cervantes is a highly accomplished professional in pharmaceutical chemistry and public health regulation. With a Master’s degree in Innovation and Technology Management from UNAM, where she earned an Honorable Mention for her thesis on the impact of transnational corporations on the pharmaceutical industry, her academic foundation is robust. She also holds a Bachelor’s degree in Pharmaceutical Chemistry Biology from UNAM, complemented by diplomas in Total Quality Control and Leadership from UPIICSA and Anáhuac University. Currently serving as the Executive Director of Analytical Control at COFEPRIS, Mrs. Guzmán Cervantes plays a pivotal role in overseeing the National Control Laboratory, ensuring the safety of products such as vaccines and medical devices. Her leadership has been instrumental in COFEPRIS’s recognition by WHO and PAHO, and she has actively contributed to international regulatory projects and workshops. Her work, including publications on the role of regulatory agencies during the COVID-19 pandemic, underscores her dedication to enhancing public health safety and regulatory standards.

Profile
Education

Mrs. Imelda Rocío Guzmán Cervantes has a robust educational background that has significantly contributed to her expertise in the fields of pharmaceutical chemistry, quality control, and innovation management. She earned her Master’s degree in Innovation and Technology Management from the Faculty of Chemistry at UNAM, where she received an Honorable Mention for her thesis on the strategies of transnational corporations and their impact on the national pharmaceutical industry. Earlier, she completed her undergraduate studies in Pharmaceutical Chemistry Biology at UNAM, where she engaged in research on the development and implementation of a master plan for validating cleaning processes in pharmaceutical production. Mrs. Guzmán Cervantes has also pursued specialized diplomas in Total Quality Control from UPIICSA and in Leadership and Personal Development from Anáhuac University. Additionally, she completed a graduate program in Management Systems Monitoring Product Safety Market at Universitat Pompeu Fabra in Barcelona, further enhancing her expertise in ensuring product safety in the healthcare sector. Her educational journey reflects a strong commitment to continuous learning and excellence in her field.

Professional Experience

Mrs. Imelda Rocío Guzmán Cervantes has built a distinguished career in pharmaceutical regulation and quality assurance. Since 2009, she has been with COFEPRIS, the Federal Commission for Protection against Sanitary Risk in Mexico, where she currently serves as the Executive Director of Analytical Control. In this role, she leads the National Control Laboratory, overseeing the analysis of vaccines, food, drugs, and medical devices to ensure their safety and efficacy. Her tenure at COFEPRIS includes significant achievements such as facilitating the agency’s recognition as a National Regulatory Authority by WHO and PAHO, and securing WHO prequalification for its laboratory. Prior to her current position, Mrs. Guzmán Cervantes worked as a Technical Advisor to the Commissioner and played a key role in establishing policies and coordinating international relationships. She also gained valuable experience as a Validation Coordinator at Protein S.A. de C.V., where she focused on quality assurance in the pharmaceutical industry. Her extensive experience underscores her commitment to enhancing public health safety and regulatory standards.

Research Interests

Mrs. Imelda Rocío Guzmán Cervantes’s research interests primarily focus on pharmaceutical regulation, quality control, and public health safety. Her work is centered on the development and implementation of regulatory frameworks and methodologies to ensure the safety and efficacy of pharmaceuticals and medical devices. She is particularly interested in the impact of regulatory practices on public health, as demonstrated by her research on the role of national regulatory agencies during the COVID-19 pandemic. Additionally, Mrs. Guzmán Cervantes explores innovations in quality control processes and the integration of international standards into national regulatory practices. Her research aims to advance the effectiveness of regulatory systems and enhance the overall safety of pharmaceutical products and medical devices.

Research Skills

Mrs. Imelda Rocío Guzmán Cervantes possesses a robust set of research skills tailored to her expertise in pharmaceutical regulation and quality control. She excels in developing and implementing regulatory frameworks and quality control processes to ensure the safety and efficacy of pharmaceutical products, medical devices, and vaccines. Her analytical skills include applying various techniques for evaluating product quality and utilizing data analysis tools to interpret research findings effectively. Mrs. Guzmán Cervantes is adept at creating detailed documentation and reports related to regulatory compliance and quality assurance. She is well-versed in international regulatory standards and practices, particularly those established by WHO and PAHO, and integrates these standards into national regulatory systems. Her project management skills enable her to oversee complex research projects, coordinate activities, and ensure adherence to regulatory requirements. Additionally, her research on the impact of regulatory agencies during health crises, such as the COVID-19 pandemic, underscores her commitment to advancing public health safety.

Awards and Recognition

Mrs. Imelda Rocío Guzmán Cervantes has received notable awards and recognition for her distinguished work in pharmaceutical regulation and quality control. Her leadership was pivotal in the recognition of COFEPRIS as a National Regulatory Authority by the World Health Organization (WHO) and the Pan American Health Organization (PAHO). Under her guidance, the National Control Laboratory (CCAYAC) achieved WHO prequalification for drug analysis, reflecting her commitment to maintaining high standards in regulatory practices. Additionally, she has been honored for her contributions as a facilitator and auditor in international regulatory workshops and evaluations, including those for GAVI countries and the Directorate General of Medicines in Peru. These accolades underscore her impactful role in advancing global public health and regulatory standards.

Conclusion

Mrs. Imelda Rocío Guzmán Cervantes’s blend of leadership, regulatory expertise, innovation in public health, and continuous dedication to professional development makes her an ideal candidate for the Health Innovator’s Leadership Award. Her contributions have had a lasting impact on both national and international public health, making her highly deserving of this recognition.

Publications Top Notes

Title: Importance of national regulatory agencies and national control laboratories in the face of the COVID-19 pandemic: Experience of Federal Commission for the Protection against Sanitary Risks (COFEPRIS)
Title (Spanish): Importancia de las agencias reguladoras nacionales y los laboratorios nacionales de control ante la pandemia de COVID-19: experiencia de la Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS)
Authors: Guzmán-Cervantes, I.R., Parra-Hernández, E., Svarch-Pérez, A.E., Zúñiga-Estrada, A., Alcocer-Varela, J.C.
Journal: Vacunas
Year: 2024
Volume: 25
Issue: 3
Pages: 424–427